Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) is now available.
ResMed Inc has announced a proposed sale of securities under Rule 144, with a director, Peter C. Farrell, planning to sell 945 common shares through Merrill Lynch. This move follows previous sales of 6,000 shares over the past three months, indicating a continued divestment by the director. The sale is scheduled for July 2, 2025, and could potentially impact the company’s stock market performance and investor sentiment, given the significant role of the director in the company.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$37.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
ResMed Inc is a company operating in the healthcare industry, primarily focusing on the development and manufacturing of equipment related to sleep disorders, particularly sleep apnea. The company’s market focus includes providing innovative solutions for respiratory care and improving the quality of life for patients with chronic respiratory conditions.
Average Trading Volume: 1,170,006
Technical Sentiment Signal: Buy
Current Market Cap: A$57.19B
For detailed information about RMD stock, go to TipRanks’ Stock Analysis page.